Design, Synthesis, and Structure−Activity Relationship, Molecular Modeling, and NMR Studies of a Series of Phenyl Alkyl Ketones as Highly Potent and Selective Phosphodiesterase-4 Inhibitors-Reference-Cited by-同舟云学术

Design, Synthesis, and Structure−Activity Relationship, Molecular Modeling, and NMR Studies of a Series of Phenyl Alkyl Ketones as Highly Potent and Selective Phosphodiesterase-4 Inhibitors

Published:2008-12-02 Issue:24 Volume:51 Page:7673-7688
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Zheng Shilong¹,Kaur Gurpreet¹,Wang Huanchen¹,Li Minyong¹,Macnaughtan Megan¹,Yang Xiaochuan¹,Reid Suazette¹,Prestegard James¹,Wang Binghe¹,Ke Hengming¹

Affiliation:

1. Department of Chemistry and Center for Biotechnology and Drug Discovery, Georgia State University, Atlanta, Georgia 30302-4098, Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, North Carolina, and Complex Carbohydrate Research Center and Department of Chemistry, University of Georgia, Athens, Georgia

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm701635j

Reference43 articles.

1. Molecular Diversity of Cyclic AMP Signalling

2. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms

3. Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use

4. Crystal Structures of Phosphodiesterases and Implications on Substrate Specificity and Inhibitor Selectivity

5. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PDE4D: A Multipurpose Pharmacological Target;International Journal of Molecular Sciences;2024-07-24

2. Roflupram alleviates autophagy defects and reduces mutant hSOD1-induced motor neuron damage in cell and mouse models of amyotrophic lateral sclerosis;Neuropharmacology;2024-01

3. Targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement;Bioorganic Chemistry;2023-01

4. Alzheimer's disease therapeutics;Privileged Scaffolds in Drug Discovery;2023

5. ZL-n-91, a specific Phosphodiesterase-4 inhibitor, suppresses the growth of triple-negative breast cancer;Investigational New Drugs;2022-06-08